Kite Pharma (KITE): Reiterating Buy Ahead of ZUMA-1 Study - Stifel

September 22, 2016 7:15 AM EDT Send to a Friend
Stifel analyst, Thomas Shrader, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) ahead of top-line data from ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login